checkAd
    Startseite > Aktien > Kiromic Biopharma > Nachrichten
    Kiromic Biopharma Aktie
    3,2000
     
    USD
    -0,62 %
    -0,0200 USD
    Letzter Kurs 02:10:00 Nasdaq OTC
    ISIN: US4976342042 · WKN: A3D7BN · SYM: KRBP · USA

    Neueste Nachrichten

    Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
    29.05.24 · Business Wire (engl.) · Kiromic Biopharma
    Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
    20.05.24 · Business Wire (engl.) · Kiromic Biopharma
    Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
    24.04.24 · Business Wire (engl.) · Kiromic Biopharma
    Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
    02.04.24 · Business Wire (engl.) · Kiromic Biopharma
    Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
    19.03.24 · Business Wire (engl.) · Kiromic Biopharma
    Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
    01.03.24 · Business Wire (engl.) · Kiromic Biopharma
    Kiromic BioPharma to Present at the OTC Markets’ Virtual Life Science Investor Forum on March 7th
    29.02.24 · Business Wire (engl.) · Kiromic Biopharma
    Results from First Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
    14.02.24 · Business Wire (engl.) · Kiromic Biopharma
    Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
    29.01.24 · Business Wire (engl.) · Kiromic Biopharma
    Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
    05.01.24 · Business Wire (engl.) · Kiromic Biopharma
     Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel for the Treatment of Non-Small Cell Lung Cancer
    14.12.23 · Business Wire (engl.) · Kiromic Biopharma
    Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14
    13.09.23 · Business Wire (engl.) · Kiromic Biopharma